Medifast (NYSE:MED) Updates Q1 2025 Earnings Guidance

Medifast (NYSE:MED) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of -0.500-0.000 for the period, compared to the consensus estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Medifast Price Performance

MED stock opened at $16.05 on Wednesday. Medifast has a 1 year low of $14.76 and a 1 year high of $49.90. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.11 and a quick ratio of 2.55. The stock has a market cap of $175.59 million, a price-to-earnings ratio of 24.32 and a beta of 1.14. The company has a 50 day simple moving average of $16.61 and a 200 day simple moving average of $18.05.

Medifast (NYSE:MED) last announced its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.26. Medifast had a net margin of 1.09% and a return on equity of 15.98%. Research analysts anticipate that Medifast will post 1.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, DA Davidson raised Medifast from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $16.50 to $17.00 in a research note on Tuesday, November 5th.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.